Quantification of the interfacial and bulk contributions to the longitudinal spin Seebeck effect

This article appeared in P. Jiménez-Cavero et al. Applied Physics Letters 118, 092404 (2021) and may be found at https://aip.scitation.org/doi/10.1063/5.0038192We report the disentanglement of bulk and interfacial contributions to the thermally excited magnon spin current in the spin Seebeck effect under static heating. For this purpose, we have studied the dependence of the inverse spin Hall voltage and the thermal conductivity on the magnetic layer thickness. Knowledge of these quantities allows us to take into account the influence of both sources of thermal spin current in the analysis of the voltage dependence. The magnetic layer thickness modulates the relative magnitude of the involved thermal drops for a fixed total thermal difference throughout the sample. In the end, we attain the separate contributions of both sources of thermal spin current—bulk and interfacial—and obtain the value of the thermal magnon accumulation length scale in maghemite, which we find to be 29(1) nm. According to our results, bulk magnon accumulation dominates the spin Seebeck effect in our studied range of thicknesses, but the interfacial component is by no means negligibleThis work was supported by the Spanish Ministry of Science [through Project Nos. MAT2014-51982-C2-R, MAT2016-80762-R, MAT2017-82970-C2-R, and PID2019-104150RB-I00 (including FEDER funding) and the Aragón Regional government (Project No. E26)]. P.J.-C. acknowledges Spanish MECD for support through FPU program (Reference No. FPU014/02546). D.B. acknowledges support from MINECO (Spain) through an FPI program (No. BES-2017-079688). R.R. also acknowledges support from the European Commission through the Project No. 734187-SPICOLOST (H2020-MSCA-RISE-2016), the European Union's Horizon 2020 research and innovation program through the Marie Sklodowska-Curie Actions Grant Agreement SPEC No. 894006, and the Spanish Ministry of Science (No. RYC 2019-026915-I). Authors acknowledge the Advanced Microscopy Laboratory-INA University of Zaragoza for offering access to their instruments. C. L-B. acknowledges Xunta de Galicia and ESF for a PhD Grant (ED481A-2018/013)S

Observation of nuclear-spin Seebeck effect

Thermoelectric effects have been applied to power generators and temperature sensors that convert waste heat into electricity. The effects, however, have been limited to electrons to occur, and inevitably disappear at low temperatures due to electronic entropy quenching. Here, we report thermoelectric generation caused by nuclear spins in a solid: nuclear-spin Seebeck effect. The sample is a magnetically ordered material MnCO3 having a large nuclear spin (I = 5/2) of 55Mn nuclei and strong hyperfine coupling, with a Pt contact. In the system, we observe low-temperature thermoelectric signals down to 100 mK due to nuclear-spin excitation. Our theoretical calculation in which interfacial Korringa process is taken into consideration quantitatively reproduces the results. The nuclear thermoelectric effect demonstrated here offers a way for exploring thermoelectric science and technologies at ultralow temperaturesThis work was supported by JST ERATO “Spin Quantum Rectification Project” (JPMJER1402), JST CREST (JPMJCR20C1 and JPMJCR20T2), JSPS KAKENHI (JP19H05600, JP19K21031, JP20H02599, JP20K22476, and JP20K15160), MEXT [Innovative Area “Nano Spin Conversion Science” (JP26103005)], and Daikin Industries, Ltd. The work at UCLA was supported by the US Department of Energy, Office of Basic Energy Sciences under Award number DE-SC0012190. K.O. acknowledges support from GP-Spin at Tohoku University. R.R. acknowledges support from the European Commission through the project 734187-SPICOLOST (H2020-MSCA-RISE-2016), the European Union’s Horizon 2020 research and innovation program through the Marie Sklodowska-Curie Actions grant agreement SPEC number 894006 and the Spanish Ministry of Science (RYC 2019-026915-I)S

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Initial invasive or conservative strategy for stable coronary disease

BACKGROUND Among patients with stable coronary disease and moderate or severe ischemia, whether clinical outcomes are better in those who receive an invasive intervention plus medical therapy than in those who receive medical therapy alone is uncertain. METHODS We randomly assigned 5179 patients with moderate or severe ischemia to an initial invasive strategy (angiography and revascularization when feasible) and medical therapy or to an initial conservative strategy of medical therapy alone and angiography if medical therapy failed. The primary outcome was a composite of death from cardiovascular causes, myocardial infarction, or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest. A key secondary outcome was death from cardiovascular causes or myocardial infarction. RESULTS Over a median of 3.2 years, 318 primary outcome events occurred in the invasive-strategy group and 352 occurred in the conservative-strategy group. At 6 months, the cumulative event rate was 5.3% in the invasive-strategy group and 3.4% in the conservative-strategy group (difference, 1.9 percentage points; 95% confidence interval [CI], 0.8 to 3.0); at 5 years, the cumulative event rate was 16.4% and 18.2%, respectively (difference, 121.8 percentage points; 95% CI, 124.7 to 1.0). Results were similar with respect to the key secondary outcome. The incidence of the primary outcome was sensitive to the definition of myocardial infarction; a secondary analysis yielded more procedural myocardial infarctions of uncertain clinical importance. There were 145 deaths in the invasive-strategy group and 144 deaths in the conservative-strategy group (hazard ratio, 1.05; 95% CI, 0.83 to 1.32). CONCLUSIONS Among patients with stable coronary disease and moderate or severe ischemia, we did not find evidence that an initial invasive strategy, as compared with an initial conservative strategy, reduced the risk of ischemic cardiovascular events or death from any cause over a median of 3.2 years. The trial findings were sensitive to the definition of myocardial infarction that was used